GLP-1 Receptor Agonists, Mortality, and CV Outcomes in Mental Illness

Дата публикации: 26-08-2026 00:00:00

This study assesses the association of glucagon-like peptide-1 receptor agonists vs sodium-glucose cotransporter-2 inhibitors with all-cause mortality and major adverse cardiovascular events among adults with and without serious mental illness.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	A Review of the Diagnosis, Treatment, and Prognosis of Bipolar Disorder	0	3.73	10-10-2023
2	VA launches trial to test GLP-1 medication for alcohol use disorder in veterans	0	4.44	30-07-2026
3	VA launches trial to test GLP-1 medication for alcohol use disorder in veterans	0	4.44	30-07-2026
4	Associations between Adherence to the 24-hour Movement Guidelines and Mental Health Indicators (Depressed Feelings and Suicide Attempt) among School-going Adolescents in Sekondi-Takoradi, Ghana: A Cross-Sectional Study	0	21.49	07-08-2026
5	Researchers test GLP-1 medications as possible treatment for opioid addiction	0	7.26	21-08-2026
6	NHS launches major study to tackle severe mental illness	0	6.62	16-02-2026
7	Can GLP-1s affect birth control, fertility?	0	7.35	15-08-2026
8	Weight Loss Medications May Affect Some Complications After Panniculectomy	0	5.94	25-03-2026
9	Оземпик неожиданно влияет на нейроны голода	0	8.46	26-08-2026
10	GLP-1s may improve outcomes in patients with PAD, diabetes	5	7	08-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 12.4. Источник: jamanetwork.com.